GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » Capital Expenditure

PT Indofarma Tbk (ISX:INAF) Capital Expenditure : Rp3,590.86 Mil (TTM As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is PT Indofarma Tbk Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

PT Indofarma Tbk's cash flow for capital expenditures for the three months ended in Sep. 2023 was Rp-2,058 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2023 was Rp3,590.86 Mil.

PT Indofarma Tbk Capital Expenditure Historical Data

The historical data trend for PT Indofarma Tbk's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Indofarma Tbk Capital Expenditure Chart

PT Indofarma Tbk Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46,768.77 -18,990.65 -13,777.29 -21,404.15 -13,475.98

PT Indofarma Tbk Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,714.03 7,778.73 -356.78 -1,773.58 -2,057.51

PT Indofarma Tbk Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp3,590.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Indofarma Tbk (ISX:INAF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » Capital Expenditure
Comparable Companies
ISX:MERK ISX:DVLA ISX:PEHA ISX:PYFA ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085
Traded in Other Exchanges
N/A
Address
Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
Website
http://www.indofarma.id
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.

PT Indofarma Tbk (ISX:INAF) Headlines

No Headlines